NeuroStar TMS Therapy, is a new FDA cleared non-medication solution for depression treatment

Reach out and get contacted by a professional!

The NeuroStar Advanced Therapy TMS device is a non-surgical procedure. No anesthesia is required.

Most insurance companies will help cover the cost of your NeuroStar Advanced Therapy TMS consultation. Find out more by contacting us today.

After your session is over, you can confidently return to any regularly scheduled activities such as work or school. 

While there may be some minor discomfort at the treatment site (where the device touches your head), it generally subsides within the first week or treatment. There is no sedation, or impact on your alertness. You can read, watch TV, or talk with your treatment coordinator during your session, and you can drive home immediately after treatment.

Over 300 million people have insurance plans that cover NeuroStar, including Medicare and Tricare. Conditions and coverage can vary by insurance company, and your NeuroStar Team Lead will help you determine your benefits and coverage. We also offer cash-pay and patient financing options if desired, talk with your NeuroStar representative for more details.

Transcranial magnetic stimulation, often referred to as TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when antidepressant medications haven’t been effective, have ceased working, or as an alternative to medication.

You’ll recline comfortably in the treatment chair. A small, curved magnetic coil will be positioned lightly on your head.

NeuroStar delivers focused magnetic stimulation directly to the target areas of the brain. You’ll hear a clicking sound and feel a tapping sensation on your head.

Because there are no effects on alertness, you can drive yourself to and from treatment sessions.

7-week session length In-office treatment recommended.

Dr. Gupta is a board-certified psychiatrist. He completed his residency training in psychiatry at the Medical College of Virginia in Richmond, Virginia. 

Dr. Gupta has worked as a staff psychiatrist at the Greenleaf Center in Valdosta, Georgia. In addition, he has worked at Behavioral Health Services of South Georgia for several years. He has extensive experience in both inpatient and outpatient psychiatry. He has been in private practice since 2001. He is a member of the American Psychiatric Association. 

Dr. Patel completed his residency training in psychiatry at the University of Tennessee, Memphis, TN. 

He has extensive experience in both inpatient and outpatient psychiatry. He has worked as a staff psychiatrist at South Georgia Medical Center and the Greenleaf Center in Valdosta, Georgia. 

He is working at Legacy Behavior Health Services since 2005. He has been in private practice at South Georgia Psychiatric and Counseling Center since 2005 and joined AR Psychiatric and Counseling Center in 2020.  

Our mission is to provide the most cutting-edge advanced, highest-quality psychiatric and counseling services in the rural counties of south Georgia.

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

Visit neurostar.com for full safety and prescribing information.